Your browser doesn't support javascript.
loading
Treatments affecting splenic function as a risk factor for valvular heart disease in Childhood Cancer Survivors: A DCCSS-LATER study.
Houtman, Bente M; Walraven, Iris; Kapusta, Livia; Teske, Arco J; van Dulmen-den Broeder, Eline; Tissing, Wim J E; van den Heuvel-Eibrink, Marry M; Versluys, A B Birgitta; Bresters, Dorine; van der Heiden-van der Loo, Margriet; Ronckers, Cécile; Kok, Wouter E M; van der Pal, Helena J H; Pluijm, Saskia M F; Janssens, Geert O; Blijlevens, Nicole M A; Kremer, Leontien C M; Loonen, Jacqueline J; Feijen, E A M Lieke.
Afiliação
  • Houtman BM; Radboudumc Center of Expertise for Cancer Survivorship, Department of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Walraven I; Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Kapusta L; Department for Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Teske AJ; Department of Pediatric Cardiology, Amalia Children's Hospital, Radboud University Medical Center, Nijmegen, The Netherlands.
  • van Dulmen-den Broeder E; Department of Pediatrics, Pediatric Cardiology Unit, Tel Aviv Sourasky Medical Center, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Tissing WJE; Department of Cardiology, University Medical Center Utrecht, Utrecht, The Netherlands.
  • van den Heuvel-Eibrink MM; Department of Pediatric Oncology, Amsterdam UMC, VU University, Amsterdam, The Netherlands.
  • Versluys ABB; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • Bresters D; Department of Pediatric Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
  • van der Heiden-van der Loo M; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • Ronckers C; Department of Pediatric Oncology, Erasmus Medical Center, Sophia Children's Hospital, Rotterdam, The Netherlands.
  • Kok WEM; Wilhelmina Children's Hospital, University Medical Center, Utrecht, The Netherlands.
  • van der Pal HJH; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • Pluijm SMF; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • Janssens GO; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • Blijlevens NMA; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • Kremer LCM; Division of Childhood Cancer Epidemiology, Institute of Medical Biostatistics, Epidemiology and Informatics (IMBEI), University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
  • Loonen JJ; Department of Cardiology Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Feijen EAML; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Pediatr Blood Cancer ; : e31251, 2024 Aug 12.
Article em En | MEDLINE | ID: mdl-39135313
ABSTRACT

PURPOSE:

Splenectomy might be a risk factor for valvular heart disease (VHD) in adult Hodgkin lymphoma survivors. As this risk is still unclear for childhood cancer survivors (CCS), the aim of this study is to evaluate the association between treatments affecting splenic function (splenectomy and radiotherapy involving the spleen) and VHD in CCS.

METHODS:

CCS were enrolled from the DCCSS-LATER cohort, consisting of 6,165 five-year CCS diagnosed between 1963 and 2002. Symptomatic VHD, defined as symptoms combined with a diagnostic test indicating VHD, was assessed from questionnaires and validated using medical records. Differences in the cumulative incidence of VHD between CCS who received treatments affecting splenic function and CCS who did not were assessed using the Gray test. Risk factors were analyzed in a multivariable Cox proportional hazards model.

RESULTS:

The study population consisted of 5,286 CCS, with a median follow-up of 22 years (5-50 years), of whom 59 (1.1%) had a splenectomy and 489 (9.2%) radiotherapy involving the spleen. VHD was present in 21 CCS (0.4%). The cumulative incidence of VHD at the age of 40 years was significantly higher in CCS who received treatments affecting splenic function (2.7%, 95% confidence interval (CI) 0.4%-4.9%) compared with CCS without (0.4%, 95% CI 0.1%-0.7%) (Gray's test, p = 0.003). Splenectomy was significantly associated with VHD in a multivariable analysis (hazard ratio 8.6, 95% CI 3.1-24.1). CONCLUSIONS AND IMPLICATIONS Splenectomy was associated with VHD. Future research is needed to determine if CCS who had a splenectomy as part of cancer treatment might benefit from screening for VHD.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article